Published: 16. October, 2024
Cessatech announces that recruitment has today reached the halfway point for patient recruitment with…
Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202
- 75 paediatric patients have now been recruited in Study 0202 •
- Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in children
- CT001 is a nasal spray for the treatment of acute pain in children
Jes Trygved, CEO, Cessatech
We are very pleased with this halfway milestone in our final study for the development of CT001 in paediatric patients. We had a slow start during the summer holiday period, but since beginning of September all sites are up and running and we have recruited more than 30 patients, this is a fantastic achievement and great effort by the team – and a potentially good indication that the product is well accepted among the involved sites. CT001 is now one step closer to finalize the clinical program and becoming available to hospitals and the children that really need approved, easy to administer pain relief.”
